Odylia co-founder Luk Vandenberghe talks to Nature about bioengineered viruses and the Odylia (non)-business model.
Researcher and entrepreneur Luk Vandenberghe thinks he can transport genes into cells much more efficiently by improving...
About Odylia
Our Path
Resources
Consortium
What we do
Odylia Therapeutics is a non-profit corporation working to bring treatments for rare eye disease from the lab into humans using genetic therapies. Today, there are more than 300 known genetic forms of Inherited Retinal Disease (IRD) that lead to blindness, with some of these interfering with other sensory mechanisms like hearing and balance. Most are extremely rare, impacting less than one in a million people worldwide.
Why we exist
Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them. Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.
Why we exist
Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them. Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.
Latest news
Stay up-to-date with our research and clinical trials
-
-
Odylia CSO speaks to the Charles River World Congress
Odylia CSO Harrison Brown speaks to the Charles River World Congress on the promises and challenges of gene therapy for ...
-
Odylia CEO speaks at NIH/NCATS conference (video)
Odylia CEO Scott Dorfman presented the Odylia concept to the National Institutes of Health and National Center for Advan...